Status:
COMPLETED
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
Lead Sponsor:
Allergopharma GmbH & Co. KG
Conditions:
Birch Pollen Allergy
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV
Eligibility Criteria
Inclusion
- Positive RAST result to birch pollen
- Positive Skin Prick Test reaction to birch pollen
- positive nasal provocation test result to birch pollen extract
Exclusion
- serious chronic diseases
- other relevant seasonal allergies
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00266526
Start Date
July 1 2003
End Date
July 1 2005
Last Update
March 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465